

| Material Issues | Related SDGs | Main Initiatives and Results | FY2022 | FY2021 | Scope of data collection | |
|--|---|---|---|--|--|----------|
| ① Innovative pharmaceuticals and healthcare services |   | Creating new drugs, adding indications, changing dosage and administration, adding formulations, and providing around the pill solutions | Number of approvals (Medium-Term Management Plan 21-25, cumulative) | 23 | 13 | (Global) |
| | | | Number of solutions provided to patients (Medium-Term Management Plan 21-25, cumulative) | 3 | 0 | (Global) |
| | | | Number of development pipelines | 20 | 27 | (Global) |
| | | | Awards received for drug discovery (total since 2007 merger) | 21 | 21 | (Global) |
| | | | Number of partnering projects (Medium-Term Management Plan 21-25, cumulative) | 11 | 6 | (Global) |
| | | Medium-Term Management Plan 21-25 new product sales volume by year | 299 packs (Therapeutic drugs for neuromyelitis optica spectrum disorders) 6,507 packs (Therapeutic drugs for tardive dyskinesia) 24,587 packs (Therapeutic drugs for amyotrophic lateral sclerosis, oral suspension) | 123 packs (Therapeutic drugs for neuromyelitis optica spectrum disorders) | (Global) | |
| ② Quality assurance and stable supply |   | Building systems for the stable supply of reliable pharmaceuticals, and appropriate responses to questions about quality | Number of product recalls (class I, II, and III) | class I 0 class II 1 class III 0 | class I 0 class II 1 class III 0 | (Japan) |
| | | | Customer satisfaction with questions about quality | 92.9% | 92.4% | (Japan) |
| ③ Appropriate use of products |   | Establishing a drug consultation center, collecting safety information, and providing information related to the appropriate use of products | Number of external presentations on clinical research (papers/academic conferences, etc.) | 84 | 77 | (Global) |
| | | | Instances of safety information collected | Domestic : 20,200 Overseas : 49,600 | Domestic : 14,600 Overseas : 54,100 | (Global) |
| ④ Access to healthcare |    | Supporting patients, developing therapeutic drugs for intractable and rare diseases, promoting project for infectious diseases that are prevalent in developing countries | Number of subsidized patient organizations (cumulative, total) | 219 | 167 | (Global) |
| | | | Number of health support website visitors | 24.25 million | 31.44 million | (Global) |
| | | | Number of pipelines for intractable and rare diseases | 9 | 9 | (Global) |
| | | | Number of approvals for intractable and rare diseases (Medium-Term Management Plan 21-25) | 3 | 1 | (Global) |
| | | | Number and stage of infectious disease treatment projects for developing countries | 3 (Non-clinical) | 2 (Non-clinical) | (Global) |
| | | | Number of health support programs in developing countries | Vaccine: 9,281 doses | Vaccine: 34,633 doses | (Global) |
| ⑤ Stakeholder engagement |  | Disseminating information and dialoging with stakeholders including customers, the general public, and employees | Employee awareness survey results (Sympathy/understanding of management philosophy, rewarding/motivation) | 77% (total favorable)*1 | 79% (total favorable)*1 | (Global) |
| | | | Customer satisfaction survey results (7-point scale) | Overall satisfaction : 5.11 Sympathy : 5.12 Necessity : 5.62 | Overall satisfaction : 5.05 Sympathy : 5.09 Necessity : 5.56 | (Japan) |
| ⑥ Employee health, diversity and inclusion |    | Promoting health management and improving work environment where all employees can play an active role | Employee survey results (Wellness item) | 84% (total favorable)*1 | 85% (total favorable)*1 | (Global) |
| | | | Employee survey results (Diversity and respect for individuals) | 79% (total favorable)*1 | 81% (total favorable)*1 | (Global) |
| | | | Diversity of management | 10.0% | 20.8% | (Global) |
| ⑦ Environment-friendly business |     | Reducing environmental impact in corporate activities and educating employees to raise environmental awareness | GHG emissions (vs. fiscal 2019) | 24.0% reduction*2 | 18.6% reduction*2 | (Global) |
| | | | Amount of water withdrawal (vs. fiscal 2019) | 36.9% reduction*2 | 30.9% reduction*2 | (Global) |
| | | | Amount of final waste disposed (vs. fiscal 2019) | 51.5% reduction*2 | 1.9% increase *2 | (Japan) |
| ⑧ Ethics, fairness and integrity |   | Working to cultivate an awareness of compliance issues, establishing and observing a variety of policies, and establishing hotlines | Surveying employee awareness on compliance (Employee awareness survey / 5 points is a perfect score) | 95% (total favorable)*1*3 | 4.51 points | (Global) |
| | | | Customer satisfaction survey results (corporate image) | Compliance : 5.15 Confidence : 5.31 | Compliance : 5.14 Confidence : 5.29 | (Japan) |

*1 : Total favorable is the total score of the top two response choices (Agree/Tend to Agree).

*2: Due to the companies included in the calculation withdrawing from business and reorganizing their facilities, results from FY2019 onwards have also changed

*3: In accordance with changes to survey methods, FY2022 results and the scope of the survey have also changed.